December 2, 2021
FHI Clinical announces its intent to acquire TCD Global, a South African-based CRO. The acquisition allows FHI Clinical to expand its share of the infectious disease (ID) clinical development market and become the dominant service provider in sub-Saharan Africa.
news & events
Check out what we’ve been up to and where can we connect!
December 2, 2021
Evaluation of early warning systems for clinical assessment of patients with COVID-19 in the global study, ACTT-1
September 21, 2021
The results from this study provide important information about the clinical management of hospitalized patients with COVID-19. Additional research is needed to identify a method that can be used to accurately prioritize patients with COVID-19 at risk of critical illness or death.
Tiziana and FHI Clinical enter a collaboration agreement for a phase 2 clinical trial of intranasal Foralumab to treat hospitalized patients with severe COVID-19
June 23, 2021
Tiziana and FHI Clinical announce collaboration on a Phase 2 study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe COVID-19 and pulmonary inflammation.
Baricitinib + remdesivir superior to remdesivir alone for hospitalized adults with COVID-19: ACTT-2 results published in NEJM
April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
November 30 – December 2, 2021
Attending the World Vaccine and Immunotherapy Congress West Coast? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event.
September 27, 2021
In this webcast we will explore the intended purpose of ICH regulations; what organizations stand to gain from adopting the updated guidelines; how organizations can improve their operational efficiencies by minimizing duplicate quality-assurance steps; strategies for quick, relatively straightforward adoption of the new guidelines.